CYP2C19 LoF alleles were associated with a significantly increased risk of MACE compared with noncarriers in clopidogrel-treated ACS patients undergoing PCI.
Does the CYP2C19 LoF allele increase the risk of MACE in ACS patients undergoing PCI and treated with clopidogrel?
The presence of the CYP2C19 LoF allele significantly increases the risk of MACE in ACS patients receiving clopidogrel post-PCI, supporting the consideration of alternative antiplatelet therapies in this population.
Absolute Event Rate: 0% vs 0%
LoF alleles, who underwent PCI and were treated with clopidogrel were correlated with significantly increased risk of MACE compared with noncarriers.
Biswas et al. (Wed,) reported a other. CYP2C19 LoF alleles were associated with a significantly increased risk of MACE compared with noncarriers in clopidogrel-treated ACS patients undergoing PCI.